Outside advisers to the Food and Drug Administration voted 7-1 yesterday in favor of using the AstraZeneca’s Brilinta to reduce the risk of heart attacks, strokes and death in patients with severe chest pain or earlier heart attacks. The panel said concerns that U.S. study participants did worse on the drug than people in other countries may be the result of chance and could be examined in a future trial after the drug is approved.
via bloomberg.com
No comments:
Post a Comment